Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

Hosuk RyouKorsuk SirinukunwattanaRuby WoodAlan AberdeenJens RittscherOlga K WeinbergRobert HasserjianOlga PozdnyakovaFrank PealeBrian HigginsPontus LundbergKerstin TrunzerClaire N HarrisonDaniel Royston

Published in: HemaSphere (2024)

Keyphrases

phase ii
bone marrow
clinical trial
open label
double blind
mesenchymal stem cells
placebo controlled
phase iii
single cell
replacement therapy
smoking cessation